What is the revenue and EPS growth rate for MindWalk year over year?

What is MindWalk's gross profit margin?

What factors drove the changes in MindWalk's revenue and profit?

What is MindWalk's latest dividend and current dividend yield?

What does MindWalk do and what are its main business segments?

What is the market's earnings forecast for MindWalk next quarter?

Did MindWalk beat or miss consensus estimates last quarter?

What guidance did MindWalk's management provide for the next earnings period?

- **Revenue Growth**: 52% YoY to $4.2 million, U.S. revenue doubles.
- **Recurring Revenue Model**: First enterprise LensAI contract signed, shifting from project-based to monthly recurring.
- **Pipeline Progress**: Dengue neutralization data imminent; influenza identifies conserved epitope across 2,000 sequences.
- **Financial Health**: Improved gross margin (58% 9-month vs 53%), $14.2M cash runway.
- **Strategic Initiatives**: B-cell Llama platform launched; asset financing in development.

**【CEO Summary Section】**
- Reported third consecutive quarter of year-over-year revenue growth, reaching $4.2 million (52% YoY increase). U.S. revenue doubled to $2.6 million.
- Signed first 1-year enterprise LensAI platform contract, transitioning from project-based to recurring revenue model.
- Pipeline advancements: Dengue program nearing neutralization testing, GLP-1 candidate shows activity relative to semaglutide, influenza program identifies conserved functional feature across 2,000 sequences.
- Launched B-cell Llama nanobody discovery platform, demonstrating function-based selection superiority.
- Exploring asset-level financing for proprietary programs (Dengue, GLP-1, influenza, B-cell Llama).

**【CFO Financial Commentary】**
- Q3 2026 revenue: $4.2 million (52% YoY), U.S. revenue: $2.6 million (100% YoY).
- Gross margin: 59% (Q3 2026) vs 65% (Q3 2025); 9-month gross margin: 58% (2026) vs 53% (2025).
- Operating expenses: R&D up 33% to $1.2 million, S&M up 67% to $1.8 million.
- Net loss: $3.9 million (Q3 2026) vs $22 million (Q3 2025, including $21.2M impairment charge).
- Cash balance: $14.2 million, supporting commercial growth and platform development.

**【Q&A Key Highlights】**
- **Enterprise Contract Driver**: Client trust built through successful project-based work, leading to recurring revenue model adoption.
- **Pipeline Conversion**: LensAI being rolled out to existing clients, with potential for additional recurring contracts.
- **Asset Financing Strategy**: Independent program advancement with internal expertise; asset-level financing being designed for future stages.

MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript

- **Strategic Reboot**: Divested non-core assets for $14.3M, repositioning as AI-driven biotech with 54% YoY revenue growth and 65% gross margin.
- **Breakthrough Assets**: GLP1 receptor agonist with semaglutide-like activity and dengue vaccine targeting conserved epitopes advance to preclinical stages.
- **Capital Efficiency**: Segregated portfolio structure enables third-party funding of assets without dilution, supported by $16.5M cash balance.
- **AI Differentiation**: HYFT patterns deliver precision in drug discovery (single best-scoring GLP1 design) and pathogen targeting (dengue serotype-agnostic epitope).
- **Growth Catalysts**: SaaS expansion, R&D investment, and strategic partnerships to accelerate AI-generated pipeline.

**【CEO Summary Section】**
- **Strategic Shift to BioNative AI**: CEO highlighted the company's pivot to focus on HYFT patterns and LensAI, divesting non-core wet lab operations in the Netherlands for $14.3M net proceeds. This repositioned MindWalk as a software-driven biotech platform.
- **Revenue Growth**: Q2 FY2026 revenue rose 54% YoY to $4.1M, with gross profit doubling to $2.7M (65% margin). This reflects higher-margin AI-driven projects and fixed cost leverage.
- **Pipeline Progress**: 
  - **GLP1 Program**: LensAI identified a single best-scoring receptor agonist with semaglutide-like activity, advancing to IND-enabling studies.
  - **Dengue Vaccine**: HYFT patterns identified a conserved epitope across all 4 serotypes, moving into preclinical planning.
  - **Longevity Program**: Dual pathway therapeutic targeting metabolic control and aging biomarkers.
- **Capital Structure**: Introduced a Cayman Islands segregated portfolio structure to house AI-generated assets, enabling third-party investment without diluting parent company equity.
- **Leadership Changes**: Appointed Scott Areglado as CFO and Dr. Thomas Lynch as CBO to strengthen financial discipline and commercialization efforts.

**【CFO Financial Commentary】**
- **Revenue Performance**: $4.1M (54% YoY growth), driven by higher-margin AI projects and improved project utilization.
- **Profitability**: 65% gross margin (vs. 51% prior year), with $2.7M gross profit (94% YoY increase). Operating loss narrowed to $2.8M (vs. $4.1M prior year).
- **Balance Sheet**: $16.5M cash post-divestiture, providing flexibility for R&D and asset development.
- **Expense Management**: Operating expenses up 12% YoY to $5.4M, with investments in R&D, sales, and G&A offset by prior year amortization.

**【Q&A Highlights】**
- **Portfolio Structure Benefits**: Segregated portfolios protect IP, allow asset-specific funding, and prevent shareholder dilution. Investors can invest directly in assets like GLP1 or dengue vaccine without equity stake in MindWalk.
- **Gross Margin Sustainability**: CEO expects continued margin expansion as scalable AI projects dominate revenue mix. Current 65% margin is not the ceiling.
- **Proceeds Allocation**: CFO plans to invest in LensAI SaaS expansion, Canadian lab operations, and R&D for internal assets.
- **Business Development Strategy**: CBO Dr. Lynch will focus on building a global sales team, deploying the SaaS model, and integrating fee-for-service work with Canadian operations.
- **Share Buybacks & ATM**: No active share buybacks. The $30M ATM facility is a long-term contingency, not an immediate fundraising tool.


MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript

- **Revenue Surge**: Q1 $7.6M (+45% YoY), driven by core AI platform and divestiture proceeds.
- **Margin Expansion**: Gross margin 53%, up from 45% YoY, with BioStrand SaaS targeting >90% margins.
- **Strategic Shift**: Transitioned to bio-native AI company (MindWalk), redefining biologics discovery with HYFT technology.
- **Vaccine Milestone**: Dengue vaccine enters preclinical trials, leveraging unique T-cell activation approach.
- **Financial Strength**: $21.1M liquidity post-divestiture, enabling SaaS expansion and R&D investments.

**【CEO Opening Remarks】**
- **Divestiture Update**: Sold Netherlands operations for $16.1M, reclassified as discontinued. Remaining operations grew 28% YoY to $3.2M, driven by core AI platform.
- **Financial Highlights**: Q1 revenue $7.6M (+45% YoY), gross profit $4M (53% margin), net loss $3M (improved from $1M YoY).
- **Rebranding Strategy**: Transitioned to MindWalk, emphasizing bio-native AI platform (HYFT) for SaaS, DaaS, and therapeutics. New ticker HYFT reflects AI-driven focus.

**【CFO Financial Commentary】**
- **Revenue Growth**: $7.6M (+45% YoY), with 53% gross margin vs. 45% prior year.
- **Expense Management**: G&A down YoY, operating loss narrowed to $2.7M from $4.2M.
- **Liquidity**: $5M cash + $16.1M divestiture proceeds, supporting SaaS investments and dengue vaccine trials.

**【Q&A Highlights】**
- **Gross Margin Breakdown**: Continued ops (53% margin) outperformed discontinued (45%). BioStrand SaaS projects target >90% margins.
- **Dengue Vaccine Progress**: Entered preclinical manufacturing with NIH collaboration. Seeking partners for Phase I trials, focusing on T-cell activation.
- **Rebranding Execution**: Balancing internal pipeline (e.g., AI-derived vaccines) with pharma partnerships for AI-driven drug discovery.

**【Closing Remarks】**
- **Strategic Focus**: Capitalized on divestiture proceeds to strengthen AI platform and pipeline. LensAI validated in derisking biologics development.
- **Future Outlook**: Scalable SaaS model, high-margin AI tools, and strategic partnerships to drive growth and value creation.

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

- **Revenue Record**: Q4 $7M (8.1% YoY), FY2025 $24.5M with 600bp margin expansion to 55%.
- **BioStrand Dominance**: 180% YoY growth, 90% margins, key to future profitability.
- **AI Breakthroughs**: LENSai outperforms benchmarks, GLP-1 peptide matches semaglutide, dengue vaccine epitope identified.
- **Strategic Shifts**: $10.8M cash, Dutch divestiture nears completion, Cambridge expansion.
- **Partnership Momentum**: $8M oncology deal, FDA-aligned AI adoption, 93% YoY new client growth.

**【CEO Summary Section】**
- **Record Q4 Revenue**: $7 million, up 8.1% YoY and 13.5% QoQ, driven by Canadian sales growth (47% YoY, 83% QoQ). 
- **Gross Margin Expansion**: 64% in Q4 (vs. 48% last year), with BioStrand segment growing 180% YoY and 90% margins.
- **Strategic Initiatives**: 
  - Dutch subsidiary divestiture nearing completion; proceeds to strengthen balance sheet.
  - Rebranding to emphasize AI-driven platform (LENSai) with HYFT technology for drug discovery.
  - Cambridge, MA expansion to tap US biotech hub.
- **Key Milestones**: 
  - FDA dengue vaccine program advance with in silico epitope mapping.
  - AI-designed GLP-1 peptide matching semaglutide in receptor assays.
  - LENSai immunogenicity screening outperforms industry benchmarks.

**【CFO Financial Commentary】**
- **FY2025 Financials**: 
  - Total revenue $24.5 million (slight increase vs. FY2024).
  - Gross profit $4.5 million (up from $3.1 million last year).
  - Operating expenses down 7% YoY to $5.8 million, driven by cost control.
  - Adjusted EBITDA loss narrows to $316K (vs. $1.7M last year).
- **Cash Position**: $10.8 million (vs. $3.5M last year), supporting growth initiatives.
- **Profitability**: 600bp gross margin expansion (49% to 55%), driven by high-margin BioStrand.

**【Q&A Highlights】**
1. **GLP-1 Peptide Development**: 
   - Partnering with manufacturers for IND-enabling data; seeking clinical sponsor.
   - Early formulation studies and dose-response data expected soon.
2. **Oncology Collaboration**: 
   - $8M partnership with biotech for antibody drug conjugates.
   - Revenue recognition begins Q2; no major milestones beyond platform success rate (>95%).
3. **FDA AI Guidance Impact**: 
   - 5% of revenue from AI services, growing rapidly with demand for in silico toxicity/immunogenicity studies.
   - LENSai's 90% accuracy in antibody-antigen mapping vs. crystallography.
4. **European Divestiture**: 
   - Final stages of sale; Canada absorbs transferred work with capacity to grow.
   - Integration of LENSai into Canadian operations enhances service offerings.


ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

- **$8M+ AI partnership launched**: Q3 2025 revenue boosted by $8M upfront payment from biotech collaboration.
- **BioStrand AI segment on fire**: 131.8% YoY growth with 97% gross margin, proving AI scalability.
- **Debt-free, cash-rich**: $8.8M equity raise + Yorkville debenture conversion gives CAD 12.9M runway.
- **GLP-1 innovation**: AI-designed molecule with transdermal delivery partner and 66% cost savings via Vultr GPUs.

**【CEO Strategic Updates】**
- Secured an $8-10M strategic partnership leveraging AI and B Cell Select technology, with $8M purchase order issued in Q3. 
- Relocated HQ to Austin, TX to expand US AI/biotech ecosystem presence.
- BioStrand AI segment achieved 131.8% YoY revenue growth (CAD 6.2M Q3) with 97% gross margin.
- Launched AI-designed GLP-1 program with parallel preclinical testing and manufacturing tracks.
- Completed $8.8M equity raise, reducing debt and extending runway to Q4 2025.

**【CFO Financial Highlights】**
- Q3 2025 revenue: CAD 6.2M (flat YoY), with CAD 0.6M from AI segment.
- Operating expenses: CAD 27.8M (incl. CAD 21.2M non-cash impairment charge).
- Net loss: CAD 21.5M (-66% YoY when excluding impairment).
- Cash balance: CAD 12.9M (up from CAD 3.5M FY24-end) after Yorkville debenture conversion.

**【Key Q&A Takeaways】**
- European divestiture expected to close by Q4 2025, reducing costs and focusing on high-margin AI/wet lab integration.
- Vultr GPU partnership delivers 66% cost savings vs traditional cloud, enabling faster AI workflows.
- Therapeutic projects now account for 48% of wet lab work (vs 19% YoY), driving higher-margin revenue.
- GLP-1 program features transdermal delivery partnership and novel sequence stability optimizations.

Actual	-0.252	-0.1362	-0.2098	-0.1573	-0.1866	-0.2968	-0.2201	-0.1427	-0.1476	-0.1061	-0.0721	-0.0818	-0.5226	-0.1086	-0.0646	-0.4541	-0.0362	-0.065	-0.0499	-0.0587
Forecast	-0.1219	-0.1362	-0.1372	-0.1967	-0.1555	-0.1328	-0.1211	-0.1728	-0.1254	-0.1554	-0.0937	-0.0744	-0.0835	-0.0797	-0.0682	-0.055	-0.0362	-0.0433	-0.0357	-0.0397
Surprise	-106.73%	0.00%	-52.92%	+20.03%	-20.00%	-123.49%	-81.75%	+17.42%	-17.70%	+31.72%	+23.05%	-9.95%	-525.87%	-36.26%	+5.28%	-725.64%	0.00%	-50.12%	-39.78%	-47.86%

HYFT

HYFT fundamentals

HYFT Q3 2026 Earnings

Earnings Call

You can ask Aime

HYFT

HYFT fundamentals

HYFT Q3 2026 Earnings

Earnings Call

HYFT Earnings Call Summary for Q3/202610:30 AM on Mar 12, 2026

HYFT Earnings Call Summary for Q2/202610:30 AM on Dec 15, 2025

HYFT Earnings Call Summary for Q1/202610:30 AM on Sep 15, 2025

HYFT Earnings Call Summary for Q4/202510:30 AM on Jul 29, 2025

HYFT Earnings Call Summary for Q3/202510:30 AM on Mar 28, 2025

You can ask Aime